# Diabetes Research Hub — Iteration Run Report

**Date:** 2026-07-23 (Thursday)
**Mode:** Automated scheduled run (no Monday weekly PubMed sweep)

## Summary

Routine maintenance run with one path reaffirmation, one opportunistic credibility-sensitive recheck, and a clean local rebuild. No net-new papers; corpus unchanged at **285 papers (272 VETTED / 13 FLAGGED, 0 unvetted)** and **57 research paths**. All papers remain vetted, so no `vet_papers_batch` was needed. No gap audits or scheduled `search_pubmed` items were due today (next audits ~2026-08; next scheduled rechecks 2026-07-27 onward).

## Work Queue Items Processed

### 1. Credibility sweep (every run) — CLEAN
- **0 fabricated PMIDs** (≥42,000,000) across all `Analysis/Scripts/*.py`.
- **0** "zero SAEs" / "zero rejection" / "no rejection" claims.
- Only 2 "curative" matches, both inside `verify_before_deploy.py` — they are the checker's own blocklist definition, not substantive claims.

### 2. validate_path — rituximab → beta_cell (reaffirmed PARTIALLY_VALIDATED)
Stalest distinct PARTIAL path (anchor **PMID 19940299**, TrialNet/Pescovitz B-cell depletion RCT, NEJM 2009). Web recheck reaffirms the existing rating with no change:
- 12-month C-peptide preservation confirmed (Pescovitz NEJM 2009).
- Effect is **transient** — Diabetes Care 2014 2-year results (**PMID 24026563**) show ~8.2-month delay in C-peptide decline that then parallels placebo as CD19+ B-cells recover (~69% of baseline by 1 year).
- 2025 network meta-analysis (**PMC12211534**, 60 RCTs / 4,597 pts) lists 11 interventions beating placebo at 12-mo C-peptide; anti-CD20/rituximab is **not** among the top performers (teplizumab, baricitinib, cyclosporin lead).
- No new 2026 rituximab RCT/MA. **No upgrade** — B-cell depletion alone does not arrest beta-cell loss.

### 3. search_pubmed / credibility recheck — NLRP3 × DKD 2026 papers (item 8, opportunistic; was due 2026-07-27)
- MDPI *Int J Mol Sci* **27(10):4257** (DOI 10.3390/ijms27104257, ferroptosis) **CONFIRMED REAL** via publisher — published 2026-05-10, **PRECLINICAL** (NLRP3-knockout diabetic mouse + HK-2 cell models; GPX4↑, ACSL4/COX2↓).
- Wiley *Immun Inflamm Dis* **iid3.70424** (Zhao, hub-gene bioinformatics) remains DOI-verified.
- **Neither has a retrievable PubMed PMID yet.** Both stay logged as `UNVETTED_NO_PMID` (pmid=PENDING, **NOT fabricated**). Re-verify PubMed indexing at next scheduled check **2026-07-27**.

## Pipeline Rebuild (Step 5) — 38/40 [OK]
- All 34 local dashboard/build stages **[OK]**, plus `validate`, `evidence`, `citations`, `pmidtracker` **[OK]**.
- 2 stages deferred: `pmidverify` (verify_pmids.py) and `ingest` (ingest_papers.py) require live PubMed/PMC API access and hang under the sandbox's restricted network — an unchanged environment limitation, not a code failure. These are network-verification steps and carry no risk to on-disk artifact integrity; next full network verify tracked under queue item 34.

## State & Queue Updates
- Recorded this run in `run_history` (now 99 entries).
- `rituximab -> beta_cell` stamped with `revisit_2026_07_23` reaffirmation.
- Rotated path-validation queue pointer to next-stalest distinct PARTIAL: **metformin → cardiovascular** (last 2026-06-25) or **oxidative_stress → T2D** therapy-arm (2026-06-30).
- Refreshed item 8 target with today's NLRP3 recheck outcome.

## Blockers (unchanged — require user)
- **Git commit/push BLOCKED.** Stale 0-byte `.git/index.lock` cannot be removed from the OneDrive mount ("Operation not permitted"), and push auth fails ("could not read Username for https://github.com"). Uncommitted work (agent_state.json + rebuilt dashboards) accumulates until the user clears the lock and commits/pushes locally.

## Constraints honored
No fabricated PMIDs or data. No overstated preclinical language. All claims trace to a source. This is research synthesis, not medical advice.
